Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Receivables (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Receivables for 16 consecutive years, with $59.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 55.31% to $59.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.6 million through Dec 2025, up 55.31% year-over-year, with the annual reading at $59.6 million for FY2025, 55.31% up from the prior year.
  • Receivables hit $59.6 million in Q4 2025 for Ligand Pharmaceuticals, up from $57.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $85.5 million in Q4 2021 to a low of $28.0 million in Q2 2023.
  • Historically, Receivables has averaged $46.2 million across 5 years, with a median of $39.9 million in 2025.
  • Biggest five-year swings in Receivables: skyrocketed 95.51% in 2021 and later tumbled 64.4% in 2022.
  • Year by year, Receivables stood at $85.5 million in 2021, then crashed by 64.4% to $30.4 million in 2022, then rose by 8.19% to $32.9 million in 2023, then rose by 16.58% to $38.4 million in 2024, then soared by 55.31% to $59.6 million in 2025.
  • Business Quant data shows Receivables for LGNDZ at $59.6 million in Q4 2025, $57.6 million in Q3 2025, and $41.3 million in Q2 2025.